Abstract:Background Stage IIIB non-small-cell lung cancer (NSCLC) is usually thought to be unresectable, and is managed with chemotherapy with or without radiotherapy. However, selected patients might benefit from surgical resection after neoadjuvant chemotherapy and radiotherapy. The aim of this multicentre, phase II trial was to assess the efficacy and toxicity of a neoadjuvant chemotherapy and radiotherapy followed by surgery in patients with technically operable stage IIIB NSCLC.Methods Between September, 2001, and May, 2006, patients with pathologically proven and technically resectable stage IIIB NSCLC were sequentially treated with three cycles of neoadjuvant chemotherapy (cisplatin with docetaxel), immediately followed by accelerated concomitant boost radiotherapy (44 Gy in 22 fractions) and definitive surgery. The primary endpoint was event-free survival at 12 months. Efficacy analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00030810.Findings 46 patients were enrolled, with a median age of 60 years (range 28-70). 13 (28%) patients had N3 disease, 36 (78%) had T4 disease. All patients received chemotherapy; 35 (76%) patients received radiotherapy. The main toxicities during chemotherapy were neutropenia (25 patients [54%] at grade 3 or 4) and febrile neutropenia (nine [20%]); the main toxicity after radiotherapy was oesophagitis (ten patients [29%]; nine grade 2, one grade 3). 35 patients (76%) underwent surgery, with pneumonectomy in 17 patients. A complete (RO) resection was achieved in 27 patients. Peri-operative complications occurred in 14 patients, including two deaths (30-day mortality 5.7%). Seven patients required a second surgical intervention. Pathological mediastinal downstaging was seen in 11 of the 28 patients who had lymph-node involvement at enrolment, a complete pathological response was seen in six patients. Event-free survival at 12 months was 54% (95% CI 39-67). After a median follow-up of 58 months, the median overall survival was 29 months (95% CI 16.1-NA), with survival at 1, 3, and 5 years of 67% (95% CI 52-79), 47% (32-61), and 40% (24-55).Interpretation A treatment strategy of neoadjuvant chemotherapy and radiotherapy followed by surgery is feasible in selected patients. Toxicity is considerable, but manageable. Survival compares favourably with historical results of combined treatment for less advanced stage IIIA disease.Funding Swiss Group for Clinical Cancer Research (SAKK) and an unrestricted educational grant by Sanofi-Aventis (Switzerland).

[Trimodal Therapy for Stage IIIA-B NSCLC Involving High Dose Neoadjuvant Chemoradiotherapy. Is Surgery a Rational Option?]

Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis

Results of Trimodality Therapy in Patients with Stage IIIA (N2-Bulky) and Stage IIIB Non-Small-cell Lung Cancer.

Surgery after multimodality treatment for non-small-cell lung cancer

Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK Trials (SAKK 16/96, 16/00, and 16/01)

Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).

International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists

Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?

Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival

Efficacy and Safety of Pembrolizumab Plus Chemotherapy and Sequential Surgical Resection in Initial Unresectable Stage IIIB NSCLC.

Trimodal therapy and surgical approaches in stage IIIA/N2 non-small cell lung cancer

Neoadjuvant Chemotherapy and Radiotherapy Followed by Surgery in Selected Patients with Stage Iiib Non-Small-Cell Lung Cancer: A Multicentre Phase Ii Trial

Induction Chemoimmunotherapy with Surgery versus Concurrent Chemoradiation followed by Immunotherapy for Stage III-N2 Non-small Cell Lung Cancer

Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment

Is There a Survival Benefit in Patients with Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy And/or Radiotherapy Prior to Surgical Resection

Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?

Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?

[The role of neoadjuvant therapy in the treatment of locally advanced, stage III non-small-cell lung cancer]

Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients

Multimodal Treatment in Operable Stage III Non-Small Cell Lung Cancer Using the New TNM Staging Classification Version 8: Long Term Results of a Pooled Analysis of Three SAKK Trials